All News

Aurobindo USA is proud to announce and welcome Paul Krauthauser as the company’s Senior Vice President of Commercial Operations reporting to Bob Cunard, Chief Executive Officer. Paul will be responsible for the retail generic business. He has more than 20 years of experience in US Pharmaceutical Sales including but not limited to demand planning, contracting […]

(March 11, 2017) WASHINGTON, DC  – “President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and affordable medicines for Americans while taking a market based, competitive approach towards lowering drug costs. Dr. Gottlieb is one of the most formidable […]

AuroMedics, a subsidiary of Aurobindo, will commence marketing the product in April 2017.

The most significant brick and mortar addition is the erecting of new 67.000 square foot facility in East Windsor, NJ. It will feature a state-of-the-art warehousing and distribution which will allow us to better serve the needs of our valued customer partners. The facility will also be the home for increased research and scientific study […]

*Source: U.S. FDA.gov publication; ending December 2016

Its new identity will improve recognition that the generic and biosimilar medicines industry is one of “the nation’s great health care success stories, and that competition from generics and biosimilars lowers the cost of medicine.” WASHINGTON — The Generic Pharmaceutical Association on Tuesday unveiled a new national effort to contain the cost of prescription medicines. […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Dalfampridine Extended-Release Tablets, 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Dalfampridine Extended-Release Tablets, 10 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Amprya® of Acorda Therapeutics, […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Telmisartan & Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Telmisartan & Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg to be bioequivalent […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Levalbuterol Inhalation Solution 0.31 mg/3 ml, 0.63 mg/3 ml, and 1.25 mg/3 ml. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Levalbuterol Inhalation Solution 0.31 mg/3 ml; 0.63 mg/3 ml; 1.25 mg/3 ml to be […]

Dayton, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Hydrocodone Bitartrate and Ibuprofen Tablets, 7.5 mg/200 mg (C-II). The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Hydrocodone Bitartrate and Ibuprofen Tablets, 7.5 mg/200 mg (C-II), to be bioequivalent and, therefore, therapeutically equivalent to the reference […]